However, since metabotropic glutamate receptors, subtype 5 (mGluR5) antagonists are being considered as an adjunctive therapy in Parkinson disease patients, D. P. wondered if alterations in mGluR5 receptor expression might somehow facilitate the formation of Lewy bodies. This evidence concerns the gene GRM5 and Parkinson disease.